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To the editor,
Favipiravir (FVP) was developed against the influenza
virus infection and licensed for the treatment of influenza
in Japan [1]. In addition to influenza viruses, FVP
demonstrates a broad-spectrum activity against many RNA
viruses including Ebola, Lassa, rabies, and severe fever
with thrombocytopenia [2]. FVP exhibited a comparable
in vitro efficacy against SARS-CoV-2 with remdesivir in a
cell culture model [3].
FVP is a prodrug and is metabolized to FVPribofuranosyl-5’-triphosphate
(FVP-RTP)
as
the
active form in cells by human hypoxanthine-guanine
phosphoribosyltransferase (HGPRT) [1]. Besides, HGPRT
is a critical enzyme in the purine salvage pathway that
converts hypoxanthine to inosine monophosphate and
guanine to guanosine monophosphate [4]. It is very well
known that dysfunctions in the purine salvage pathway
(i.e. low HGPRT activity) manifest with elevated uric
acid levels. In this study, it was hypothesized that the
patients with high serum uric acid levels may have lower
HGPRT activity hindering the conversion of FVP to its
active metabolite, which might, in turn, lead to a delayed
response to FVP treatment in COVID-19 patients.
Patients over 18 years, admitted for COVID-19 between
March 23 and June 23, 2020, were recruited in this crosssectional study. Institutional review board approval was
granted from the Hacettepe University Ethical Committee
for Non-interventional Studies (GO 20/354). The patients
were closely followed up, and routine blood tests were
repeated on days 3 and 5 of their admission. Favipiravir
was administered 1600 mg BID as an oral loading dose
followed by 600 mg BID for 4 days. Standard of care
treatments was given to all patients. Endpoints were defined
as time-to-defervescence (body temperature <38°C), time-
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to-hospital discharge, and death. Serum uric acid levels
were recorded at hospital admission, and all analyses were
based on these results. People with underlying conditions
(i.e. gout, chronic renal failure) and on medications (i.e.
diuretics, allopurinol) that may affect serum uric acid
levels were excluded. Because baseline serum uric acid
levels were compatible with normal distribution, a cut-off
point of 5 mg/dL (median value of the recruited cohort)
was constituted to categorize the cohort into low and high
uric acid groups.
Data of 80 confirmed patients were analyzed in this
study. The mean age of the patients was 54.5 ± 16.9 years,
and 47.5% (n = 39) of the patients were women. Disease
severity was comparable between low and high uric acid
groups (p = 0.104). Low and high uric acid groups were
comparable in terms of comorbidities (p > 0.05). The mean
baseline uric acid level was 5.1 ± 1.9 mg/dL. The patients
were divided into two groups as those with uric acid level
<5 mg/dL (low) (48.8%, n = 39) and ≥5 mg/dL (high)
(51.3%, n = 41). The mean level of baseline lymphocyte,
neutrophil-lymphocyte ratio (NLR), C-reactive protein
(CRP), ferritin, D-dimer, fibrinogen, ALT, AST, ALP,
GGT, LDH were not statistically different between high
and low uric acid groups. Only BUN and creatinine were
higher in the high uric acid group (p < 0.001 and p <
0.001, respectively). Time to hospital discharge (THD)
was 8.5 (1–45) and 9.5 (2–67) days in low uric acid and
high uric acid groups, respectively (p = 0.389) (Table).
The fatality rate was 12.2% (5/41) and 2.6% (1/39) in the
high uric acid group and the low uric acid, respectively
(p = 0.102). The median baseline uric acid level of those
who died was 5.79 (4.90–7.60) mg/dL, and 4.94 (1.95–
10.40) mg/dL in recovered patients (p = 0.168). Time to
defervescence (TTD) was achieved in 5.00 ± 5.35 days
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Table. Comparison of the changes in laboratory findings on the 3rd and 5th days between groups.
Low uric acid group, median
(minimum, maximum)

High uric acid group, median
(minimum, maximum)

p-value*

Change from baseline on the 3rd day of FVP
Lymphocyte (106/L)

395

(–2040, 780)

95

(–420, 900)

0.975

NLR

–1.08

(–8.14, 14.96)

–0.25

(–10.72, 34.33)

0.176

CRP (mg/dL)

–0.28

(–9.90, 10.73)

2.73

(–8.30, 21.60)

0.011

LDH (U/L)

–32

(–302, 204)

21

(–372, 333)

0.282

Ferritin (µg/L)

24.5

(–449, 695)

13.2

(–259, 3323)

0.875

D-dimer (mg/L)

0.05

(–3.44, 0.89)

0.06

(–22.53, 37.58)

0.003

Fibrinogen (mg/dL)

29.60

(–216.00, 68.00)

54.01

(–83.00, 387.54)

0.409

ALT (U/L)

10

(–5, 98)

–0.5

(–26, 34)

0.147

AST (U/L)

4

(–17, 109)

0

(–35, 78)

0.959

Change from baseline on the 5th day of FVP
Lymphocyte (106/L)

385

(–1390, 750)

95

(–450, 1170)

0.289

NLR

–0.31

(–9.11, 21.62)

–0.41

(–10.56, 13.69)

0.945

CRP (mg/dL)

–0.11

(–10.77, 46.13)

–0.23

(–8.30, 27.40)

0.920

LDH (U/L)

–6.5

(–304, 140)

14

(–606, 345)

0.255

Ferritin (µg/L)

28

(–637, 760)

196

(–269, 2973)

0.132

D-dimer (mg/L)

–0.04

(–3.07, 1.28)

0.10

(–24.17, 39.77)

0.883

Fibrinogen (mg/dL)

37

(–144, 415)

114

(–210, 370)

0.139

ALT (U/L)

16

(–5, 96)

5

(–11, 218)

0.872

AST (U/L)

6

(–45, 83)

5

(–12, 151)

0.437

* Mann–Whitney U test was used for statistical analysis.

with FVP treatment. TTD was 3.64 ± 4.60 and 5.94 ± 5.68
days in the low and high uric acid groups, respectively (p
= 0.075).
This study has some limitations. First, it is a singlecenter study with a limited number of patients. Second,
follow-up on the virological cure was not available. Followup was not available beyond the hospital stay, and only
in-hospital events were recorded. Serum and intracellular
FVP levels and HGPRT activity were not defined.
Regardless, this study is the first to explore the possible
association of baseline uric acid levels and the outcome of
FVP treatment among COVID-19 patients. In this cohort
of consecutive cases treated with FVP, excluding patients
with underlying conditions/comedications that might
affect serum uric acid levels, our results indicate that
people with low baseline uric acid levels do not respond
better to FVP treatment than the patients with higher uric
acid levels.
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